<dd id='qApWV'><tbody id='gljIV'><td id='nadGh'><optgroup id='SXRRX'><strong id='hABeM'></strong></optgroup><address id='mdiyW'><ul id='8plov'></ul></address><big id='QGmSy'></big></td><table id='vZxix'></table></tbody><pre id='PZFYM'></pre></dd><span id='jBdd1'><b id='Z0ljI'></b></span>
<dfn id='Y7I9w'><optgroup id='85qjo'></optgroup></dfn><tfoot id='9u82S'><bdo id='ixECt'><div id='RrFk2'></div><i id='Zc4wr'><dt id='FyRbE'></dt></i></bdo></tfoot>
<ul id='84vCB'></ul>
<fieldset id='cLpqu'></fieldset>
禮來公(gong)司宣布與OpenAI合(he)作，這將使禮來公(gong)司能夠利用OpenAI的生(sheng)成式人工智能發明新型抗(kang)菌劑來治療耐(nai)藥病(bing)原(yuan)體。抗(kang)微生(sheng)物藥物耐(nai)藥性（AMR）是全球衛生(sheng)領域最大的公(gong)共衛生(sheng)和發展(zhan)威脅(xie)之一。(美(mei)通社(she))
<dd id='a17o4'><tbody id='a17o4'><td id='a17o4'><optgroup id='a17o4'><strong id='a17o4'></strong></optgroup><address id='a17o4'><ul id='a17o4'></ul></address><big id='a17o4'></big></td><table id='a17o4'></table></tbody><pre id='a17o4'></pre></dd><span id='a17o4'><b id='a17o4'></b></span>
<dfn id='a17o4'><optgroup id='a17o4'></optgroup></dfn><tfoot id='a17o4'><bdo id='a17o4'><div id='a17o4'></div><i id='a17o4'><dt id='a17o4'></dt></i></bdo></tfoot>
<ul id='a17o4'></ul>
<fieldset id='a17o4'></fieldset>
